|
26 Companies |
|
33 Products |
|
33 Products |
|
27 Mechanisms of Action |
|
0 Trials |
|
159 News |
|
| 123» |
- | Trial completion: FitKidney: Facilitating Improvements in Kidney Health Using a Smartphone App Counseling Program in Patients With Diabetes (clinicaltrials.gov) - Mar 1, 2019
P=N/A, N=50, Completed, Sponsor: Geisinger Clinic
Active, not recruiting --> Completed
- | Trial completion, Enrollment change: RCP-MM: Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple Myeloma (clinicaltrials.gov) - Sep 11, 2018
P=N/A, N=30, Completed, Sponsor: Rennes University Hospital
Active, not recruiting --> Completed Recruiting --> Completed | N=50 --> 30
- | allopurinol / Generic mfg.
Trial completion: MIKAL: Microalbuminuria and Allopurinol in Type 1 Diabetes (clinicaltrials.gov) - Sep 10, 2018
P4, N=30, Completed, Sponsor: Peter Rossing
Recruiting --> Completed | N=50 --> 30 Active, not recruiting --> Completed
- | Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Trial completion: DapKid: Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes (clinicaltrials.gov) - Sep 10, 2018
P4, N=40, Completed, Sponsor: Peter Rossing
Active, not recruiting --> Completed Recruiting --> Completed
- | Xinlay (atrasentan) / Novartis
Phase classification: A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors (clinicaltrials.gov) - Jun 6, 2018
P2a, N=92, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Completed Phase classification: P2 --> P2a
- | Phase classification, Enrollment change: Evaluation of Albuminuria HIV-Infected Patients (clinicaltrials.gov) - Apr 6, 2018
P, N=252, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase classification: P2 --> P2a Phase classification: P=N/A --> P | N=134 --> 252
- | Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: FitKidney: Facilitating Improvements in Kidney Health Using a Smartphone App Counseling Program in Patients With Diabetes (clinicaltrials.gov) - Feb 28, 2018
P=N/A, N=45, Active, not recruiting, Sponsor: Geisinger Clinic
Phase classification: P=N/A --> P | N=134 --> 252 Enrolling by invitation --> Active, not recruiting | N=240 --> 45 | Trial primary completion date: Jun 2018 --> Feb 2019 | Trial completion date: Jun 2021 --> Feb 2019
- Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Trial completion, Trial primary completion date: TRANSLATE: Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects (clinicaltrials.gov) - Jan 16, 2018
P4, N=10, Completed, Sponsor: University Health Network, Toronto
Enrolling by invitation --> Active, not recruiting | N=240 --> 45 | Trial primary completion date: Jun 2018 --> Feb 2019 | Trial completion date: Jun 2021 --> Feb 2019 Recruiting --> Completed | Trial primary completion date: Sep 2017 --> Apr 2017
- | losartan / Generic mfg.
Trial completion: ReDNeph: Resveratrol's Effects in Diabetic Nephropathy (clinicaltrials.gov) - Oct 5, 2017
P, N=60, Completed, Sponsor: Shiraz University of Medical Sciences
Recruiting --> Completed | Trial primary completion date: Sep 2017 --> Apr 2017 Recruiting --> Completed
- | Biomarker, Trial completion, Enrollment change: Does Micro-albuminuria is a Predictive Factor for Cognitive Impairment in Persons Living With HIV (PLHIV) Who Achieve cART-sustained Immunovirological Control ? (clinicaltrials.gov) - Jul 28, 2017
P=N/A, N=82, Completed, Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Recruiting --> Completed Recruiting --> Completed | N=120 --> 82
- | Trial completion, Enrollment change, Trial primary completion date: World Trade Center (WTC) RENAL (clinicaltrials.gov) - Jul 23, 2017
P=N/A, N=406, Completed, Sponsor: Icahn School of Medicine at Mount Sinai
Recruiting --> Completed | N=120 --> 82 Enrolling by invitation --> Completed | N=550 --> 406 | Trial primary completion date: Jun 2017 --> Sep 2016
- | Trial completion: CKD/ESRD-MIT: Medication Intervention in Transitional Care to Optimize Outcomes & Costs for CKD & ESRD (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=120, Completed, Sponsor: Providence Medical Research Center
Enrolling by invitation --> Completed | N=550 --> 406 | Trial primary completion date: Jun 2017 --> Sep 2016 Active, not recruiting --> Completed
- ||||||| Minnebro (esaxerenone) / Daiichi Sankyo
Trial completion: Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria (clinicaltrials.gov) - Apr 4, 2017
P3, N=51, Completed, Sponsor: Daiichi Sankyo Co., Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| ASP8232 / Astellas
Trial completion: A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease (clinicaltrials.gov) - Mar 28, 2017
P2, N=125, Completed, Sponsor: Astellas Pharma Europe B.V.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe
Trial completion: CANVAS-R: A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Mar 27, 2017
P4, N=5681, Completed, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Enrollment open: FitKidney: Facilitating Improvements in Kidney Health Using a Smartphone App Counseling Program in Patients With Diabetes (clinicaltrials.gov) - Mar 7, 2017
P=N/A, N=240, Enrolling by invitation, Sponsor: Geisinger Clinic
Active, not recruiting --> Completed Not yet recruiting --> Enrolling by invitation
- | Trial completion, Enrollment change: ABC-AVC: Prognostic Value of Cardiac and Renal Markers in Ischemic Stroke and Transient Ischemic Attack (clinicaltrials.gov) - Feb 27, 2017
P=N/A, N=159, Completed, Sponsor: University Hospital, Tours
Not yet recruiting --> Enrolling by invitation Recruiting --> Completed | N=300 --> 159
- | Minnebro (esaxerenone) / Daiichi Sankyo
Enrollment closed: Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria (clinicaltrials.gov) - Feb 23, 2017
P3, N=50, Active, not recruiting, Sponsor: Daiichi Sankyo Co., Ltd.
Recruiting --> Completed | N=300 --> 159 Recruiting --> Active, not recruiting
- Arxxant (ruboxistaurin oral) / Eli Lilly, Takeda
Trial completion: The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes (clinicaltrials.gov) - Jan 31, 2017
P2, N=0, Completed, Sponsor: Chromaderm, Inc.
Recruiting --> Active, not recruiting No longer recruiting --> Completed
- New trial: FitKidney: Facilitating Improvements in Kidney Health Using a Smartphone App Counseling Program in Patients With Diabetes (clinicaltrials.gov) - Jan 10, 2017
P=N/A, N=240, Not yet recruiting, Sponsor: Geisinger Clinic
- Trial completion, Enrollment change: Early Identification and Action in CKD (clinicaltrials.gov) - Nov 15, 2016
P=N/A, N=47, Completed, Sponsor: Geisinger Clinic
No longer recruiting --> Completed Active, not recruiting --> Completed | N=93 --> 47
- | carvedilol / Generic mfg., metoprolol succinate / Generic mfg.
Trial termination: COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria (clinicaltrials.gov) - Oct 25, 2016
P3, N=1220, Terminated, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed | N=93 --> 47 Completed --> Terminated
- losartan / Generic mfg.
Trial primary completion date: ReDNeph: Resveratrol's Effects in Diabetic Nephropathy (clinicaltrials.gov) - Oct 11, 2016
P0, N=60, Recruiting, Sponsor: Shiraz University of Medical Sciences
Completed --> Terminated Trial primary completion date: Aug 2016 --> Dec 2016
- Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
New P4 trial: DapKid: Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes (clinicaltrials.gov) - Sep 26, 2016
P4, N=40, Recruiting, Sponsor: Peter Rossing
- |||| imarikiren (TAK-272) / Takeda
Trial completion: A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria (clinicaltrials.gov) - Sep 9, 2016
P2, N=415, Completed, Sponsor: Takeda
Trial primary completion date: Aug 2016 --> Dec 2016 Recruiting --> Completed
- Trial completion, Enrollment change: Correlation of Albuminuria With Arterial Stiffness (clinicaltrials.gov) - Aug 30, 2016
P=N/A, N=152, Completed, Sponsor: Istanbul University
Recruiting --> Completed Recruiting --> Completed | N=456 --> 152
- ||| ASP8232 / Astellas
Enrollment closed, Trial primary completion date: A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease (clinicaltrials.gov) - Aug 25, 2016
P2, N=125, Active, not recruiting, Sponsor: Astellas Pharma Europe B.V.
Recruiting --> Completed | N=456 --> 152 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Oct 2016
- Januvia (sitagliptin) / Merck (MSD)
Enrollment change, Trial termination: Use of Sitagliptin to Decrease Microalbuminuria (clinicaltrials.gov) - Aug 23, 2016
P4, N=142, Terminated, Sponsor: University of Missouri-Columbia
N=110 --> 142 | Recruiting --> Terminated; Original Principal Investigator left institution. No data analyzed.
- | Victoza (liraglutide) / Novo Nordisk
Trial completion: LIRALBU: Antiproteinuric Effects of Liraglutide Treatment (clinicaltrials.gov) - Aug 10, 2016
P4, N=32, Completed, Sponsor: Steno Diabetes Center
No data analyzed. Recruiting --> Completed
- Biomarker, New trial: Does Micro-albuminuria is a Predictive Factor for Cognitive Impairment in Persons Living With HIV (PLHIV) Who Achieve cART-sustained Immunovirological Control ? (clinicaltrials.gov) - Aug 2, 2016
P=N/A, N=120, Recruiting, Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
- | Minnebro (esaxerenone) / Daiichi Sankyo
Enrollment open: Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria (clinicaltrials.gov) - Jul 20, 2016
P3, N=50, Recruiting, Sponsor: Daiichi Sankyo Co., Ltd.
Recruiting --> Completed Not yet recruiting --> Recruiting
- allopurinol / Generic mfg.
New P4 trial: MIKAL: Microalbuminuria and Allopurinol in Type 1 Diabetes (clinicaltrials.gov) - Jul 12, 2016
P4, N=30, Active, not recruiting, Sponsor: Peter Rossing
- ||| Minnebro (esaxerenone) / Daiichi Sankyo
New P3 trial: Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria (clinicaltrials.gov) - Jun 21, 2016
P3, N=50, Not yet recruiting, Sponsor: Daiichi Sankyo Co., Ltd.
- Trial primary completion date: World Trade Center (WTC) RENAL (clinicaltrials.gov) - May 18, 2016
P=N/A, N=550, Enrolling by invitation, Sponsor: Icahn School of Medicine at Mount Sinai
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2016 --> Jun 2017
- losartan / Generic mfg.
Enrollment open: ReDNeph: Resveratrol's Effects in Diabetic Nephropathy (clinicaltrials.gov) - Apr 8, 2016
P0, N=60, Recruiting, Sponsor: Shiraz University of Medical Sciences
Trial primary completion date: Jun 2016 --> Jun 2017 Not yet recruiting --> Recruiting
- Enrollment closed, Trial primary completion date: CKD/ESRD-MIT: Medication Intervention in Transitional Care to Optimize Outcomes & Costs for CKD & ESRD (clinicaltrials.gov) - Apr 4, 2016
P=N/A, N=120, Active, not recruiting, Sponsor: Providence Medical Research Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Dec 2015
- | paricalcitol / Generic mfg.
Trial completion, Trial primary completion date: Oral Paricalcitol in Renal Transplant Recipients for Reducing Albuminuria (clinicaltrials.gov) - Mar 30, 2016
P3, N=77, Completed, Sponsor: Oslo University Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Dec 2015 Not yet recruiting --> Completed | Trial primary completion date: Jan 2014 --> Jan 2015
- || ASP8232 / Astellas
Trial primary completion date: A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease (clinicaltrials.gov) - Mar 25, 2016
P2, N=110, Recruiting, Sponsor: Astellas Pharma Europe B.V.
Not yet recruiting --> Completed | Trial primary completion date: Jan 2014 --> Jan 2015 Trial primary completion date: Jun 2016 --> Jan 2017
- losartan / Generic mfg.
New trial: ReDNeph: Resveratrol's Effects in Diabetic Nephropathy (clinicaltrials.gov) - Mar 10, 2016
P0, N=60, Not yet recruiting, Sponsor: Shiraz University of Medical Sciences
- Trial primary completion date: Early Identification and Action in CKD (clinicaltrials.gov) - Feb 17, 2016
P=N/A, N=93, Active, not recruiting, Sponsor: Geisinger Clinic
Trial primary completion date: Jun 2016 --> Jan 2017 Trial primary completion date: Nov 2015 --> Mar 2016
- ||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion: MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin (clinicaltrials.gov) - Dec 25, 2015
P3, N=360, Completed, Sponsor: Boehringer Ingelheim
Trial primary completion date: Nov 2015 --> Mar 2016 Active, not recruiting --> Completed
- | Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
New P4 trial: TRANSLATE: Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects (clinicaltrials.gov) - Oct 23, 2015
P4, N=12, Recruiting, Sponsor: University Health Network, Toronto
- Enrollment closed, Trial primary completion date: Early Identification and Action in CKD (clinicaltrials.gov) - Oct 13, 2015
P=N/A, N=93, Active, not recruiting, Sponsor: Geisinger Clinic
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Nov 2015
- | Victoza (liraglutide) / Novo Nordisk
New P4 trial: LIRALBU: Antiproteinuric Effects of Liraglutide Treatment (clinicaltrials.gov) - Sep 10, 2015
P4, N=32, Recruiting, Sponsor: Steno Diabetes Center
- Trial completion: Lowering Salt Intake in Chronic Kidney Disease: A Pilot Randomized Crossover Trial (clinicaltrials.gov) - Aug 12, 2015
P=N/A, N=35, Completed, Sponsor: University of Michigan
Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Nov 2015 Active, not recruiting --> Completed
- ||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Enrollment closed: MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin (clinicaltrials.gov) - Jun 26, 2015
P3, N=350, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion, Trial primary completion date: RAND: Albuminuria Reduction With Renin Angiotensin System Inhibitors in SCA Patients (clinicaltrials.gov) - Jun 18, 2015
P=N/A, N=53, Completed, Sponsor: Assistance Publique - H
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Sep 2014
- ||| Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe
Enrollment closed, Trial primary completion date: CANVAS-R: A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Jun 16, 2015
P4, N=5865, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Sep 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Jan 2017
- Trial primary completion date: RCP-MM: Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple Myeloma (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=50, Recruiting, Sponsor: Rennes University Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Jan 2017 Trial primary completion date: Dec 2014 --> Jan 2018
- Tekturna (aliskiren) / PDL
New trial: Influence of Aliskiren on Albuminuria After Kidney Transplantation (clinicaltrials.gov) - May 19, 2015
P=N/A, N=18, Completed, Sponsor: Medical University of Gdansk